{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:32:39Z","timestamp":1791689559055,"version":"4.3.4"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.bone.2019.115048","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T10:51:21Z","timestamp":1566643881000},"page":"115048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Off-label uses of denosumab in metabolic bone diseases"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symeon","family":"Tournis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2019.115048_bb0005","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/13543780903048929","article-title":"RANKL inhibition for the management of patients with benign metabolic bone disorders","volume":"18","author":"Anastasilakis","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bone.2019.115048_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/TCRM.S24239","article-title":"Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab","volume":"8","author":"Anastasilakis","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bone.2019.115048_bb0015","series-title":"StatPearls. Treasure Island (FL)","author":"Hildebrand","year":"2018"},{"key":"10.1016\/j.bone.2019.115048_bb0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/eem.09.35","article-title":"Paget\u2019s disease of bone: emphasis on treatment with zoledronic acid","volume":"4","author":"Polyzos","year":"2009","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0025","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.bone.2012.01.020","article-title":"Paget's disease of the bone after treatment with Denosumab: a case report","volume":"50","author":"Schwarz","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115048_bb0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.therap.2016.07.003","article-title":"Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function","volume":"72","author":"Kostine","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.bone.2019.115048_bb0035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.47102\/annals-acadmedsg.V47N12p528","article-title":"C. Er, Effective treatment of Paget\u2019s disease of the bone in a Chinese woman","volume":"47","author":"Kuthiah","year":"2018","journal-title":"Ann. Acad. Med. Singap."},{"key":"10.1016\/j.bone.2019.115048_bb0040","first-page":"103","article-title":"Giant cell tumor developing in Paget\u2019s disease of Bone: a case report with review of literature","volume":"6","author":"Verma","year":"2016","journal-title":"J Orthop Case Rep"},{"key":"10.1016\/j.bone.2019.115048_bb0045","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3892\/ol.2017.5693","article-title":"Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget\u2019s disease: a case report","volume":"13","author":"Tanaka","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bone.2019.115048_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.metabol.2017.10.007","article-title":"Juvenile Paget disease","volume":"80","author":"Polyzos","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.bone.2019.115048_bb0055","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","article-title":"Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget\u2019s disease","volume":"98","author":"Grasemann","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0060","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1210\/jc.2013-3762","article-title":"Denosumab treatment for juvenile Paget\u2019s disease: results from two adult patients with osteoprotegerin deficiency (\u201cBalkan\u201d mutation in the TNFRSF11B gene)","volume":"99","author":"Polyzos","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0065","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00774-010-0198-8","article-title":"Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget\u2019s disease","volume":"28","author":"Polyzos","year":"2010","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0070","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jbmr.3602","article-title":"Activation of RANK\/RANKL\/OPG pathway is involved in the pathophysiology of fibrous dysplasia and associated with disease burden","volume":"34","author":"de Castro","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0075","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154680","article-title":"Receptor-activator of nuclear KappaB ligand expression as a new therapeutic target in primary Bone tumors","volume":"11","author":"Yamagishi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2019.115048_bb0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jbspin.2014.04.013","article-title":"Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment","volume":"81","author":"Benhamou","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bone.2019.115048_bb0090","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00198-013-2585-1","article-title":"Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases","volume":"25","author":"Ganda","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.115048_bb0095","first-page":"253","article-title":"Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia","volume":"13","author":"Eller-Vainicher","year":"2016","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.bone.2019.115048_bb0100","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates","author":"Majoor","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0105","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s00198-016-3719-z","article-title":"Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease","volume":"27","author":"Dede","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.115048_bb0110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1359\/jbmr.040113","article-title":"Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle","volume":"19","author":"Morabito","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4103\/2230-8210.137516","article-title":"Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis","volume":"18","author":"Yassin","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.bone.2019.115048_bb0120","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/bloodadvances.2018023085","article-title":"Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial","volume":"2","author":"Voskaridou","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bone.2019.115048_bb0125","first-page":"1","article-title":"2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"2011","author":"KDIGO","year":"2017","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.bone.2019.115048_bb0130","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jbmr.2406","article-title":"Bone mineral density predicts fractures in chronic kidney disease","volume":"30","author":"West","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0135","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0140","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","article-title":"Safety and efficacy of denosumab in osteoporotic hemodialysed patients","volume":"30","author":"Festuccia","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.bone.2019.115048_bb0150","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10067-016-3447-y","article-title":"Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density","volume":"36","author":"Cheng","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bone.2019.115048_bb0155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1053\/j.ajkd.2015.03.012","article-title":"Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial","volume":"66","author":"Hiramatsu","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bone.2019.115048_bb0160","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6218129","article-title":"Denosumab for male hemodialysis patients with low bone mineral density: a case-control study","author":"Takami","year":"2017","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.bone.2019.115048_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3676","article-title":"Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial","author":"Iseri","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0170","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1210\/jc.2014-1154","article-title":"An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis","volume":"99","author":"Chen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0175","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jc.2015-1259","article-title":"Effects of Denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low Bone mass","volume":"100","author":"Chen","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"34","key":"10.1016\/j.bone.2019.115048_bb0180","first-page":"1014","article-title":"Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5","volume":"41","author":"Dave","year":"2015","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.bone.2019.115048_bb0185","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.ajkd.2012.06.019","article-title":"Severe hypocalcemia following denosumab injection in a hemodialysis patient","volume":"60","author":"McCormick","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bone.2019.115048_bb0190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bone.2019.07.006","article-title":"Bone disease following solid organ transplantation: a narrative review and recommendations for management from the European Calcified Tissue Society","volume":"127","author":"Anastasilakis","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115048_bb0195","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fendo.2018.00162","article-title":"Osteoporosis therapy with Denosumab in organ transplant recipients","volume":"9","author":"Brunova","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bone.2019.115048_bb0200","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfy411","article-title":"Effect of denosumab on trabecular bone score in de novo kidney transplant recipients","author":"Bonani","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bone.2019.115048_bb0205","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/ajt.13692","article-title":"Effect of twice-yearly Denosumab on prevention of Bone mineral density loss in De novo kidney transplant recipients: a randomized controlled trial","volume":"16","author":"Bonani","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.bone.2019.115048_bb0210","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1159\/000447930","article-title":"Effect of Denosumab on peripheral compartmental Bone density, microarchitecture and estimated Bone strength in De novo kidney transplant recipients","volume":"41","author":"Bonani","year":"2016","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.bone.2019.115048_bb0215","first-page":"175","article-title":"Initial experience of Denosumab treatment for osteoporosis after kidney transplantation","volume":"108","author":"Maehana","year":"2017","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"10.1016\/j.bone.2019.115048_bb0220","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1620\/tjem.238.205","article-title":"Combination therapy of Denosumab and calcitriol for a renal transplant recipient with severe bone loss due to therapy-resistant hyperparathyroidism","volume":"238","author":"Wada","year":"2016","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.bone.2019.115048_bb0225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/ckj\/sfs158","article-title":"Dramatic increase in parathyroid hormone and hypocalcaemia after denosumab in a kidney transplanted patient","volume":"6","author":"Torregrosa","year":"2013","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.bone.2019.115048_bb0230","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/imj.13744","article-title":"Acute hypocalcaemia following denosumab in heart and lung transplant patients with osteoporosis","volume":"48","author":"Shrosbree","year":"2018","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.bone.2019.115048_bb0235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.metabol.2017.06.001","article-title":"Osteogenesis imperfecta - a clinical update","volume":"80","author":"Tournis","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.bone.2019.115048_bb0240","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bone.2019.115048_bb0245","first-page":"183","article-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI","volume":"12","author":"Semler","year":"2012","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bone.2019.115048_bb0250","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect\u2013a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bone.2019.115048_bb0255","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years' experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.bone.2019.115048_bb0260","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00223-016-0110-1","article-title":"Osteogenesis imperfecta type VI in individuals from northern Canada","volume":"98","author":"Ward","year":"2016","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2019.115048_bb0265","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbrc.2009.11.139","article-title":"PEDF regulates osteoclasts via osteoprotegerin and RANKL","volume":"391","author":"Akiyama","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2019.115048_bb0270","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jocd.2018.09.001","article-title":"TBS as a tool to differentiate the impact of Antiresorptives onCortical and trabecular Bone in children with OsteogenesisImperfecta","volume":"22","author":"Rehberg","year":"2019","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2019.115048_bb0275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1620\/tjem.242.115","article-title":"Efficacy of Denosumab for osteoporosis in three female patients with osteogenesis imperfecta","volume":"242","author":"Uehara","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.bone.2019.115048_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7120479","article-title":"Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis-case series","volume":"7","author":"Kobayashi","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bone.2019.115048_bb0285","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.bone.2019.115048_bb0290","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115048_bb0295","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3324\/haematol.2010.034553","article-title":"Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis","volume":"96","author":"Zanotti","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2019.115048_bb0300","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","article-title":"Denosumab for the treatment of mastocytosis-related osteoporosis: a case series","volume":"100","author":"Orsolini","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2019.115048_bb0305","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.medcli.2017.10.010","article-title":"Maxillar osteonecrosis associated to denosumab in a patient with systemic mastocytosis","volume":"151","author":"Sanchez Lopez","year":"2018","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.bone.2019.115048_bb0310","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11910-001-0012-z","article-title":"Diagnosis and management of neurofibromatosis type 1","volume":"1","author":"Korf","year":"2001","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.bone.2019.115048_bb0315","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2147\/TCRM.S159668","article-title":"Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report","volume":"14","author":"Uehara","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bone.2019.115048_bb0320","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1148\/radiographics.14.1.8128043","article-title":"Skeletal complications of radiation therapy","volume":"14","author":"Bluemke","year":"1994","journal-title":"Radiographics"},{"key":"10.1016\/j.bone.2019.115048_bb0325","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/jbmr.2519","article-title":"Response to denosumab treatment for 2 years in an adolescent with osteoradionecrosis","volume":"30","author":"Vazquez","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0330","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMra1311488","article-title":"Multiple-system atrophy","volume":"372","author":"Fanciulli","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2019.115048_bb0335","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2147\/TCRM.S162574","article-title":"Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis","volume":"14","author":"Uehara","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bone.2019.115048_bb0340","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1542\/peds.2018-0333E","article-title":"Bone health and osteoporosis management of the patient with Duchenne muscular dystrophy","volume":"142","author":"Ward","year":"2018","journal-title":"Pediatrics"},{"issue":"Cd010899","key":"10.1016\/j.bone.2019.115048_bb0345","article-title":"Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy","volume":"1","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2019.115048_bb0350","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2106\/JBJS.CC.17.00190","article-title":"Efficacy of Denosumab for glucocorticoid-induced osteoporosis in an adolescent patient with Duchenne muscular dystrophy: a case report","volume":"8","author":"Kumaki","year":"2018","journal-title":"JBJS Case Connect"},{"key":"10.1016\/j.bone.2019.115048_bb0355","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1007\/s00586-017-5114-7","article-title":"Evidence-based prevention and treatment of osteoporosis after spinal cord injury: a systematic review","volume":"27","author":"Soleyman-Jahi","year":"2018","journal-title":"Eur. Spine J."},{"key":"10.1016\/j.bone.2019.115048_bb0360","article-title":"Reasons for initiation and discontinuation of pharmacological therapies of osteoporosis in veterans with spinal cord injury and disorder","author":"Le","year":"2019","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2019.115048_bb0365","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00198-015-3333-5","article-title":"Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury","volume":"27","author":"Gifre","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.115048_bb0370","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1007\/s00198-017-4090-4","article-title":"Effect of recent spinal cord injury on the OPG\/RANKL system and its relationship with bone loss and the response to denosumab therapy","volume":"28","author":"Gifre","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.115048_bb0375","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.amjmed.2015.06.031","article-title":"Medical complications of anorexia nervosa and bulimia","volume":"129","author":"Westmoreland","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2019.115048_bb0380","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.bone.2011.09.054","article-title":"RANKL\/RANK\/OPG system and bone status in females with anorexia nervosa","volume":"50","author":"Ostrowska","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115048_bb0385","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.amjmed.2015.07.040","article-title":"Use of Denosumab in a patient with chronic anorexia nervosa and osteoporosis","volume":"129","author":"Jamieson","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2019.115048_bb0390","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115048_bb0395","article-title":"Hypophosphatasia in adults: clinical spectrum and its association with genetics and metabolic substrates","author":"Lefever","year":"2018","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2019.115048_bb0400","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s00198-015-3149-3","article-title":"Presentation and management of osteoporosis presenting in association with pregnancy or lactation","volume":"26","author":"Kovacs","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.115048_bb0405","article-title":"Risk factors, fractures, and management of pregnancy-associated osteoporosis: a retrospective study of 14 Turkish patients","author":"Tuna","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.bone.2019.115048_bb0410","first-page":"244","article-title":"Two cases of pregnancy- and lactation- associated osteoporosis successfully treated with denosumab","volume":"13","author":"Sanchez","year":"2016","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.bone.2019.115048_bb0415","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.tjog.2017.10.028","article-title":"Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: a case study","volume":"56","author":"Ijuin","year":"2017","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.bone.2019.115048_bb0420","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0425","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.metabol.2017.08.002","article-title":"Clinical and experimental aspects of notch receptor signaling: Hajdu-Cheney syndrome and related disorders","volume":"80","author":"Canalis","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.bone.2019.115048_bb0430","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2016.08.025","article-title":"Hajdu Cheney syndrome; report of a novel NOTCH2 mutation and treatment with denosumab","volume":"92","author":"Adami","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115048_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2017.03.005","article-title":"Letter to the Editor concerning \"Hajdu Cheney syndrome; report of a novel NOTCH2 mutation and treatment with denosumab\" by G. Adami et al. Bone 2016; 92:150-156","volume":"101","author":"Jerzakowski","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115048_bb0440","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-8-72","article-title":"Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of euro-Histio-net","volume":"8","author":"Girschikofsky","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.bone.2019.115048_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathol-020712-163959","article-title":"Pathogenesis of Langerhans cell histiocytosis","volume":"8","author":"Badalian-Very","year":"2013","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bone.2019.115048_bb0450","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/adc.2008.144527","article-title":"Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland","volume":"94","author":"Salotti","year":"2009","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2019.115048_bb0455","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.tem.2007.06.003","article-title":"Endocrine manifestations in Langerhans cell histiocytosis","volume":"18","author":"Makras","year":"2007","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0460","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1084\/jem.20041785","article-title":"Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis","volume":"201","author":"Costa","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bone.2019.115048_bb0465","doi-asserted-by":"crossref","first-page":"E618","DOI":"10.1210\/jc.2011-2962","article-title":"Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis","volume":"97","author":"Makras","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0470","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1210\/jc.2014-2654","article-title":"Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis","volume":"100","author":"Makras","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0475","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.metabol.2017.01.004","article-title":"Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis","volume":"69","author":"Makras","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.bone.2019.115048_bb0480","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.joms.2017.09.013","article-title":"Denosumab as a treatment alternative for central Giant cell granuloma: a long-term retrospective cohort study","volume":"76","author":"Bredell","year":"2018","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.115048_bb0485","first-page":"10","article-title":"Immunohistochemical expression of mast cell in oral reactive lesions","volume":"16","author":"Shojaei","year":"2015","journal-title":"J Dent (Shiraz)"},{"key":"10.1016\/j.bone.2019.115048_bb0490","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/j.joms.2014.06.456","article-title":"Management of central giant cell granuloma with subcutaneous denosumab therapy","volume":"72","author":"Naidu","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.115048_bb0495","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.joms.2014.02.017","article-title":"Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab","volume":"72","author":"Schreuder","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.115048_bb0500","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/ams.ams_192_18","article-title":"Denosumab treatment for aggressive multiple recurrent familial central giant-cell granulomas","volume":"8","author":"Rytkonen","year":"2018","journal-title":"Ann Maxillofac Surg"},{"key":"10.1016\/j.bone.2019.115048_bb0505","doi-asserted-by":"crossref","first-page":"E601","DOI":"10.1097\/BRS.0000000000000862","article-title":"Effect of denosumab on recurrent giant cell reparative granuloma of the lumbar spine","volume":"40","author":"Akeda","year":"2015","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.bone.2019.115048_bb0510","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bjoms.2019.05.023","article-title":"Management of an aggressive giant cell granuloma of the mandible with denosumab: a case report","volume":"57","author":"Hameed","year":"2019","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2019.115048_bb0515","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.3390\/brainsci9050105","article-title":"Benign giant cell lesion of C1 lateral mass: a case report and literature review","volume":"9","author":"Heinrich","year":"2019","journal-title":"Brain Sci"},{"key":"10.1016\/j.bone.2019.115048_bb0520","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26926","article-title":"Denosumab treatment in aneurysmal bone cyst: evaluation of nine cases","volume":"65","author":"Kurucu","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bone.2019.115048_bb0525","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0300891618784808","article-title":"Denosumab in patients with aneurysmal bone cysts: a case series with preliminary results","volume":"104","author":"Palmerini","year":"2018","journal-title":"Tumori"},{"key":"10.1016\/j.bone.2019.115048_bb0530","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.trsl.2014.03.005","article-title":"Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response","volume":"164","author":"Pelle","year":"2014","journal-title":"Transl. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.otsr.2019.04.028","article-title":"Denosumab for treating aneurysmal bone cysts in children","author":"Raux","year":"2019","journal-title":"Orthop Traumatol Surg Res"},{"key":"10.1016\/j.bone.2019.115048_bb0540","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00586-013-2715-7","article-title":"Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts","volume":"22","author":"Lange","year":"2013","journal-title":"Eur. Spine J."},{"key":"10.1016\/j.bone.2019.115048_bb0545","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7819-12-17","article-title":"Response of an aggressive periosteal aneurysmal bone cyst (ABC) of the radius to denosumab therapy","volume":"12","author":"Pauli","year":"2014","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.bone.2019.115048_bb0550","doi-asserted-by":"crossref","first-page":"E1201","DOI":"10.1097\/BRS.0000000000001027","article-title":"Response of aneurysmal bone cyst to denosumab","volume":"40","author":"Skubitz","year":"2015","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.bone.2019.115048_bb0555","doi-asserted-by":"crossref","first-page":"E654","DOI":"10.1097\/BRS.0000000000001350","article-title":"Interest of Denosumab for the treatment of Giant-cells tumors and aneurysmal bone cysts of the spine","volume":"41","author":"Dubory","year":"2016","journal-title":"About Nine Cases, Spine (Phila Pa 1976)"},{"key":"10.1016\/j.bone.2019.115048_bb0560","first-page":"3692","article-title":"Denosumab: non-surgical treatment option for selective arterial embolization resistant aneurysmal bone cyst of the spine and sacrum. Case report","volume":"20","author":"Ghermandi","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bone.2019.115048_bb0565","first-page":"9125493","article-title":"Therapeutic management of a substantial pelvic aneurysmatic bone cyst including the off-label use of denosumab in a 35-year-old female patient","volume":"2017","author":"Ntalos","year":"2017","journal-title":"Case Rep Orthop"},{"key":"10.1016\/j.bone.2019.115048_bb0570","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/BRS.0000000000002017","article-title":"Efficacy and safety of selective arterial embolization in the treatment of aneurysmal bone cyst of the mobile spine: a retrospective observational study","volume":"42","author":"Terzi","year":"2017","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.bone.2019.115048_bb0575","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1002\/hed.25438","article-title":"Massive aneurysmal bone cyst of the skull base treated with denosumab","volume":"40","author":"Asi","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.bone.2019.115048_bb0580","article-title":"Recurrent aneurysmal bone cyst of the distal fibula treated with denosumab and curettage","volume":"2018","author":"Fontenot","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.bone.2019.115048_bb0585","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00586-018-5528-x","article-title":"Denosumab: a potential treatment option for aneurysmal bone cyst of the atlas","volume":"27","author":"Patel","year":"2018","journal-title":"Eur. Spine J."},{"key":"10.1016\/j.bone.2019.115048_bb0590","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1051\/sicotj\/2019007","article-title":"Denosumab: a potential new treatment option for recurrent aneurysmal Bone cyst of the spine","volume":"5","author":"Kulkarni","year":"2019","journal-title":"SICOT J"},{"key":"10.1016\/j.bone.2019.115048_bb0595","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bjd.14366","article-title":"Buschke-Ollendorff syndrome: a novel case series and systematic review","volume":"174","author":"Pope","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bone.2019.115048_bb0600","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13256-018-1820-y","article-title":"Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report","volume":"12","author":"Byberg","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.bone.2019.115048_bb0605","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.bdj.2017.412","article-title":"Beyond ONJ - a review of the potential uses of bisphosphonates in dentistry","volume":"222","author":"Shah","year":"2017","journal-title":"Br. Dent. J."},{"key":"10.1016\/j.bone.2019.115048_bb0610","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jcms.2017.10.011","article-title":"Denosumab as a potential treatment alternative for patients suffering from diffuse sclerosing osteomyelitis of the mandible-a rapid communication","volume":"46","author":"Otto","year":"2018","journal-title":"J. Craniomaxillofac. Surg."},{"key":"10.1016\/j.bone.2019.115048_bb0615","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1002\/ccr3.1894","article-title":"Treatment of diffuse sclerosing osteomyelitis of the jaw with denosumab shows remarkable results-a report of two cases","volume":"6","author":"Hallmer","year":"2018","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.bone.2019.115048_bb0620","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/bonekey.2015.124","article-title":"Treatment of bone marrow lesions (bone marrow edema)","volume":"4","author":"Eriksen","year":"2015","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.bone.2019.115048_bb0625","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.injury.2017.02.020","article-title":"Denosumab is effective in the treatment of bone marrow oedema syndrome","volume":"48","author":"Rolvien","year":"2017","journal-title":"Injury"},{"key":"10.1016\/j.bone.2019.115048_bb0630","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.rh.2019.01.001","article-title":"Idiopathic bone marrow oedema: outcome of 3 cases treated with denosumab","volume":"53","author":"Zaldibar Barinaga","year":"2019","journal-title":"Rehabilitacion (Madr)"},{"key":"10.1016\/j.bone.2019.115048_bb0635","article-title":"Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee","author":"Muller","year":"2019","journal-title":"Knee Surg. Sports Traumatol. Arthrosc."},{"key":"10.1016\/j.bone.2019.115048_bb0640","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2106\/JBJS.J.01834","article-title":"Pathophysiology and new strategies for the treatment of Legg-Calve-Perthes disease","volume":"94","author":"Kim","year":"2012","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.bone.2019.115048_bb0645","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/17453674.2017.1298020","article-title":"Denosumab and surgery for the treatment of Perthes\u2019 disease in a 9-year-old boy: favorable course documented by comprehensive imaging- a case report","volume":"88","author":"Meiss","year":"2017","journal-title":"Acta Orthop."},{"key":"10.1016\/j.bone.2019.115048_bb0650","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/jbmr.3376","article-title":"Effect of zoledronic acid and denosumab in patients with low back pain and modic change: a proof-of-principle trial","volume":"33","author":"Cai","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0655","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.CC.18.00285","article-title":"Gorham-stout syndrome of the shoulder girdle successfully controlled by antiresorptive agents: a report of 2 cases","volume":"9","author":"Matsumoto","year":"2019","journal-title":"JBJS Case Connect"},{"key":"10.1016\/j.bone.2019.115048_bb0660","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2169\/internalmedicine.2118-18","article-title":"Fatal progression of Gorham-Stout disease with Skull Base osteomyelitis and lateral medullary syndrome","volume":"58","author":"Nozawa","year":"2019","journal-title":"Intern. Med."},{"key":"10.1016\/j.bone.2019.115048_bb0665","article-title":"Mandibular Gorham-Stout disease: a case report and literature review","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bone.2019.115048_bb0670","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jdiacomp.2018.04.010","article-title":"A review of bone metabolism and developments in medical treatment of the diabetic Charcot foot","volume":"32","author":"Jansen","year":"2018","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.bone.2019.115048_bb0675","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/17453674.2015.1033606","article-title":"Role of Wnt\/beta-catenin and RANKL\/OPG in bone healing of diabetic Charcot arthropathy patients","volume":"86","author":"Folestad","year":"2015","journal-title":"Acta Orthop."},{"key":"10.1016\/j.bone.2019.115048_bb0680","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.2337\/dc17-1517","article-title":"Effect of single dose of RANKL antibody treatment on acute Charcot neuro-osteoarthropathy of the foot","volume":"41","author":"Busch-Westbroek","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2019.115048_bb0685","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11926-013-0371-x","article-title":"Osteoporosis and orthopedic surgery: effect of bone health on total joint arthroplasty outcome","volume":"15","author":"Russell","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bone.2019.115048_bb0690","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bone.2011.01.009","article-title":"Bisphosphonates in orthopedic applications","volume":"49","author":"Wilkinson","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115048_bb0695","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bone.2010.09.024","article-title":"Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening","volume":"48","author":"Aspenberg","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.115048_bb0700","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12891-016-1036-5","article-title":"Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Skoldenberg","year":"2016","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bone.2019.115048_bb0705","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.metabol.2017.10.003","article-title":"Bone disease in primary hyperparathyroidism","volume":"80","author":"Makras","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.bone.2019.115048_bb0710","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective effect of denosumab on bone in older women with primary hyperparathyroidism","volume":"66","author":"Eller-Vainicher","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.bone.2019.115048_bb0715","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0885066613507530","article-title":"Hypercalcemia in the intensive care unit: a review of pathophysiology, diagnosis, and modern therapy","volume":"30","author":"Maier","year":"2015","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.bone.2019.115048_bb0720","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/ijem.IJEM_678_18","article-title":"Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction","volume":"23","author":"Rajan","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.bone.2019.115048_bb0725","article-title":"Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy","volume":"2015","author":"Jumpertz von Schwartzenberg","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.bone.2019.115048_bb0730","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/imj.13508","article-title":"Denosumab-induced hypophosphataemia in a case of normocalcaemic primary hyperparathyroidism","volume":"47","author":"Konrade","year":"2017","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.bone.2019.115048_bb0735","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ckj\/sft014","article-title":"Prolonged hypocalcaemia following a single dose of 60 mg denosumab in two patients with CKD 4\/5 on cinacalcet treatment for tertiary hyperparathyroidism","volume":"6","author":"Ivanov","year":"2013","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.bone.2019.115048_bb0740","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jamda.2009.02.015","article-title":"Hypercalcemia of immobilization","volume":"10","author":"Labossiere","year":"2009","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.bone.2019.115048_bb0745","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13730-017-0254-5","article-title":"Denosumab for treatment of immobilization-related hypercalcemia in a patient with end-stage renal disease","volume":"6","author":"Uehara","year":"2017","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.bone.2019.115048_bb0750","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/1319-2442.198239","article-title":"Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient","volume":"28","author":"Dahmani","year":"2017","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.bone.2019.115048_bb0755","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2013-4205","article-title":"Using denosumab to treat immobilization hypercalcemia in a post-acute care patient","volume":"99","author":"Booth","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0760","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/ckj\/sfs116","article-title":"Denosumab for treatment of immobilization-related hypercalcaemia in a patient with advanced renal failure","volume":"5","author":"de Beus","year":"2012","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.bone.2019.115048_bb0765","article-title":"Successful treatment of tuberculosis-associated hypercalcemia with denosumab in a patient with acute kidney injury","author":"Torres-Ortiz","year":"2018","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.bone.2019.115048_bb0770","doi-asserted-by":"crossref","first-page":"83","DOI":"10.14310\/horm.2002.1225","article-title":"Medical treatment of hypercalcaemia","volume":"8","author":"Makras","year":"2009","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.bone.2019.115048_bb0775","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"THERAPY OF ENDOCRINE DISEASE: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2019.115048_bb0780","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bone.2019.115048_bb0785","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1210\/jc.2012-1792","article-title":"Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab","volume":"97","author":"Khoury","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.115048_bb0790","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0002-9343(77)90843-9","article-title":"Acute myelofibrosis and malignant hypercalcemia","volume":"62","author":"Libnoch","year":"1977","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2019.115048_bb0795","first-page":"105","article-title":"Hypercalcemia and adrenal insufficiency in a patient with myelofibrosis","volume":"63","author":"Hertzberg","year":"2000","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bone.2019.115048_bb0800","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1016\/j.metabol.2017.06.003","article-title":"Lipodystrophy: time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications","volume":"72","author":"Polyzos","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.bone.2019.115048_bb0805","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1136\/bmj.39582.589433.BE","article-title":"Diagnosis and management of hypocalcaemia","volume":"336","author":"Cooper","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2019.115048_bb0810","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","article-title":"Clinical vertebral fractures following denosumab discontinuation","volume":"54","author":"Polyzos","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.bone.2019.115048_bb0815","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","volume":"27","author":"Anastasilakis","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.115048_bb0820","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","author":"Anastasilakis","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.115048_bb0825","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif. Tissue Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219303382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219303382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:43:21Z","timestamp":1757612601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219303382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":165,"alternative-id":["S8756328219303382"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.115048","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-label uses of denosumab in metabolic bone diseases","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.115048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115048"}}